Last reviewed · How we verify

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. — Portfolio Competitive Intelligence Brief

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
SSGJ-707 SSGJ-707 phase 3 PD-1/PD-L1 inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
  2. Hanlim Pharm. Co., Ltd. · 2 shared drug classes
  3. AstraZeneca · 2 shared drug classes
  4. Beijing Tiantan Hospital · 2 shared drug classes
  5. EMS · 2 shared drug classes
  6. GlaxoSmithKline · 2 shared drug classes
  7. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
  8. Merck Sharp & Dohme LLC · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.:

Cite this brief

Drug Landscape (2026). Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sunshine-guojian-pharmaceutical-shanghai-co-ltd. Accessed 2026-05-16.

Related